Assertio Holdings Reports Q2 2025 Revenue Decline and Increased Net Loss

Assertio Holdings, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $29.2 million, a decrease of 6% from $31.1 million in the same period of 2024. The decline was primarily attributed to a drop in product sales, which fell to $28.8 million from $30.7 million year-over-year. The company experienced a net loss of $16.4 million, or $0.17 per share, compared to a net loss of $3.7 million, or $0.04 per share, in the prior year. For the first half of 2025, total revenues were $55.7 million, down from $63.6 million in the first half of 2024, with a net loss of $29.9 million compared to $8.2 million in the same period last year.

The financial performance reflects significant changes in product sales, particularly for INDOCIN, which saw a sharp decline from $6.9 million to $3.0 million due to increased competition from generic products. Conversely, sales of ROLVEDON, the company’s lead product, increased slightly to $16.1 million, bolstered by higher volume and adjustments to prior period reserves. However, the overall pricing environment remains challenging, with expectations of continued pressure from discounts and rebates impacting future sales.

Strategically, Assertio completed the divestiture of Assertio Therapeutics on May 9, 2025, which resulted in an $8.2 million loss recognized in the second quarter. This divestiture was part of a broader strategy to streamline operations and focus on core products. Additionally, the company ceased the commercialization of Otrexup in July 2025, incurring one-time costs associated with this decision. The restructuring efforts, including workforce reductions, are expected to yield long-term efficiencies, although they have contributed to increased expenses in the short term.

Operationally, Assertio's total assets decreased to $273.8 million as of June 30, 2025, down from $284.7 million at the end of 2024. The company reported cash and cash equivalents of $47.1 million, alongside short-term investments of $51.1 million. The employee headcount has been adjusted as part of the restructuring plan, which is anticipated to conclude by the end of 2025. The company continues to focus on enhancing its product portfolio and market presence, particularly in oncology and neurology.

Looking ahead, Assertio anticipates ongoing challenges in the competitive landscape, particularly with the introduction of generics and pricing pressures. The company is committed to optimizing its operations and expects to leverage its existing cash reserves to support its strategic initiatives. Management remains focused on improving the commercial success of ROLVEDON and other products while navigating the complexities of the pharmaceutical market.